A Phase 3 interventional study of Risankizumab and Ustekinumab in Psoriasis, sponsored by AbbVie. Completed at 53 sites in 7 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-05-20.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.
Among the 30 studies testing risankizumab in Psoriasis, this one is the 17th largest by enrollment, is one of 3 that started in 2020, is one of 17 in phase 3, and was the 20th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 162 across the 30 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 29th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2020, is one of 31 in phase 3, and was the 63rd registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing risankizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants with moderate to severe plaque psoriasis. This study will assess the change in disease symptoms.
Risankizumab is a drug being studied for the treatment for plaque psoriasis in pediatric participants. This study has 4 parts.
Part 1: Participants aged 12 \< 18 will receive a fixed dose of risankizumab. Part 2: Participants aged 12 \< 18 will receive;
Part 3: Participants aged 6 \< 12 will receive risankizumab based on body weight.
Part 4: Participants aged 6 \< 12 will receive risankizumab based on body weight (Japan only: Participants aged 12 > 18 will receive risankizumab based on body weight).
Around 132 participants will be enrolled in approximately 50 sites worldwide.
Risankizumab and ustekinumab are given as a subcutaneous (under the skin) injection.
Parts 1, 3, and 4: Risankizumab for 40 weeks with a follow-up call 20 weeks later for a study duration of approximately 65 weeks.
Part 2:
There may be a higher burden for study participants compared to standard treatment. Participants will attend monthly visits and medical assessments will check the effect of treatment through blood tests, questionnaires, and checking for side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.
Drug: Risankizumab
Participants age 12 to less than 18 will receive: Period A: Ustekinumab Dose A, Dose B, or Dose C based on body weight for 16 weeks (at Week 0 and Week 4). Period B: Risankizumab Dose A or B based on body weight for 24 weeks.
Drug: Risankizumab · Drug: Ustekinumab
Participants age 12 to less than 18 will receive: Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4). Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare. Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4).
Drug: Risankizumab
Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
Drug: Risankizumab
Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks (Japan only: participants age 12 to less than 18 years will be included).
Drug: Risankizumab
Subcutaneous Injection
Also known as: SKYRIZI, ABBV-066
Subcutaneous Injection
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.
Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1)
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).
Time frame: At Week 16 of initial treatment in each part of the study (Parts 1-4)
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).
Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.
Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.
Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (0 or 1)
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).
Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).
Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.
Time frame: Baseline (Week 0) to Week 16 of initial treatment in each part of the study (Parts 1-4)
Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.
Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.
Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.
Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Percentage of Participants Achieving PASI 75 (Defined as at Least 75% Improvement in PASI)
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.
Time frame: Baseline (Week 0) and Week 16 of the re-treatment phase in Part 2 (Period C)
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.
Time frame: Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score
The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.
Time frame: Baseline (Week 0) to Week 16 of the re-treatment phase in Part 2 (Period C)
Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score
The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.
Time frame: Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)
Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score
The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.
Time frame: Baseline (Week 0) to Week 16 of the re-treatment phase in Part 2 (Period C)
Change From Baseline in Itch Numerical Rating Scale (Itch NRS)
The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.
Time frame: Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)
Change From Baseline in Itch Numerical Rating Scale (Itch NRS)
The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.
Time frame: Baseline (Week 0) to Week 16 of the re-treatment phase in Part 2 (Period C)
Percentage of Participants Achieving >= 4-point Improvement in the Itch Numerical Rating Scale (in Participants With Baseline Score >= 4)
The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch within a 24-hour recall period. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving \>= 4 point improvement in the itch NRS in participants with a baseline itch NRS score of \>=4.
Time frame: Baseline (Week 0) to Week 16 of initial treatment in Part 2 (Period A)
| Milestone | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 2 Period A: Ustekinumab; Period B: Risankizumab | Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal | Part 2 Period C: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 2 Period A: Ustekinumab; Period B: Risankizumab | Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal | Part 2 Period C: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 28 | 54 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 28 | 53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 2 Period A: Ustekinumab; Period B: Risankizumab | Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal | Part 2 Period C: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 28 | 10 | 22 | 21 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 28 | 10 | 22 | 21 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 2 Period A: Ustekinumab; Period B: Risankizumab | Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal | Part 2 Period C: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 2 Period A: Ustekinumab; Period B: Risankizumab | Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal | Part 2 Period C: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 2 Period A: Ustekinumab; Period B: Risankizumab | Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal | Part 2 Period C: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other than specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.
| percentage of participants | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI) | 83.3 (51.6 to 97.9) | 85.7 (67.3 to 96.0) | 85.2 (72.9 to 93.4) | 92.3 (64.0 to 99.8) | 86.7 (69.3 to 96.2) |
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).
| percentage of participants | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) | 83.3 (51.6 to 97.9) | 75.0 (55.1 to 89.3) | 79.6 (66.5 to 89.4) | 84.6 (54.6 to 98.1) | 90.0 (73.5 to 97.9) |
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).
| percentage of participants | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear or Almost Clear (Score of 0 or 1) and With at Least 2 Grade Improvement From Baseline | 83.3 (51.6 to 97.9) | 67.9 (47.6 to 84.1) | 68.5 (54.4 to 80.5) | 84.6 (54.6 to 98.1) | 83.3 (65.3 to 94.4) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.
| percentage of participants | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|
| Percentage of Participants Achieving PASI 90 (Defined as at Least 90% Improvement in PASI) | 83.3 (51.6 to 97.9) | 60.7 (40.6 to 78.5) | 64.8 (50.6 to 77.3) | 84.6 (54.6 to 98.1) | 76.7 (57.7 to 90.1) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.
| percentage of participants | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|
| Percentage of Participants Achieving PASI 100 (Defined as at Least 100% Improvement in PASI) | 41.7 (15.2 to 72.3) | 17.9 (6.1 to 36.9) | 40.7 (27.6 to 55.0) | 53.8 (25.1 to 80.8) | 43.3 (25.5 to 62.6) |
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).
| percentage of participants | Part 2 Period C: Risankizumab |
|---|---|
| Baseline (Week 0) | 12.5 (0.3 to 52.7) |
| Week 16 | 62.5 (24.5 to 91.5) |
The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe) with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving sPGA of clear (score of 0) or almost clear (score of 1).
| percentage of participants | Part 2 Period C: Risankizumab |
|---|---|
| Baseline (Week 0) | 0.0 (0.0 to 36.9) |
| Week 16 | 62.5 (24.5 to 91.5) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.
| percentage of participants | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|
| Percentage of Participants Achieving PASI 50 (Defined as at Least 50% Improvement in PASI) | 91.7 (61.5 to 99.8) | 92.9 (76.5 to 99.1) | 90.7 (79.7 to 96.9) | 100 (75.3 to 100.0) | 96.7 (82.8 to 99.9) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 50% improvement in PASI.
| percentage of participants | Part 2 Period C: Risankizumab |
|---|---|
| Baseline (Week 0) | 75.0 (34.9 to 96.8) |
| Week 16 | 87.5 (47.3 to 99.7) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 90% improvement in PASI.
| percentage of participants | Part 2 Period C: Risankizumab |
|---|---|
| Baseline (Week 0) | 37.5 (8.5 to 75.5) |
| Week 16 | 87.5 (47.3 to 99.7) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 100% improvement in PASI.
| percentage of participants | Part 2 Period C: Risankizumab |
|---|---|
| Baseline (Week 0) | 0 (0.0 to 36.9) |
| Week 16 | 25.0 (3.2 to 65.1) |
The PASI is used to evaluate a participant's overall psoriasis disease state that includes the percent of surface area of skin that is affected and the severity of erythema, induration, and desquamation over four body regions (head, upper extremities, trunk, and lower extremities). Scores range from 0 to 72, with the highest score representing the worst outcome (complete erythroderma of the severest degree). Data are reported for the percentage of participants achieving at least a 75% improvement in PASI.
| percentage of participants | Part 2 Period C: Risankizumab |
|---|---|
| Baseline (Week 0) | 37.5 (8.5 to 75.5) |
| Week 16 | 87.5 (47.3 to 99.7) |
The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.
| score on a scale | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab |
|---|---|---|
| Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score | -6.8 ± 0.66 | -7.4 ± 0.49 |
The CDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on quality of life (QOL). The CDLQI items include symptoms and feelings, daily activities, leisure, school, relationships, sleep, and treatment. Each item was scored on a 4-point scale: 0 = not at all; 1 = only a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.
| score on a scale | Part 2 Period C: Risankizumab |
|---|---|
| Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score | -7.5 ± 2.88 |
The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.
| score on a scale | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab |
|---|---|---|
| Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score | -6.0 ± 0.84 | -6.9 ± 0.60 |
The FDLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of dermatologic disease symptoms and treatment on Quality of Life (QOL) of family members. It consists of 10 questions that assess the impact of skin diseases on different aspects of the family member's QOL. Each item was scored on a 4-point scale: 0 = not at all; 1 = a little; 2 = quite a lot; and 3 = very much. Item scores (0 to 3) were added to provide a total score range of 0 to 30 with higher scores representing greater impairment of QOL and worse outcomes. A negative change from baseline score indicated a reduced impairment of QOL.
| score on a scale | Part 2 Period C: Risankizumab |
|---|---|
| Change From Baseline in Family Dermatology Life Quality Index (FDLQI) Total Score | -5.8 ± 3.29 |
The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.
| score on a scale | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab |
|---|---|---|
| Change From Baseline in Itch Numerical Rating Scale (Itch NRS) | -2.9 ± 0.50 | -3.8 ± 0.38 |
The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. A negative change from baseline indicates less intense itching and better outcomes.
| score on a scale | Part 2 Period C: Risankizumab |
|---|---|
| Change From Baseline in Itch Numerical Rating Scale (Itch NRS) | -2.8 ± 1.68 |
The itch NRS is an 11-point scale that participants complete to describe the intensity of their itch within a 24-hour recall period. The itch NRS scale scores varies between 0, representing "no itching" and 10, representing "worst itch imaginable" with higher scores representing worse outcomes. Data are reported for the percentage of participants achieving \>= 4 point improvement in the itch NRS in participants with a baseline itch NRS score of \>=4.
| percentage of participants | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab |
|---|---|---|
| Percentage of Participants Achieving >= 4-point Improvement in the Itch Numerical Rating Scale (in Participants With Baseline Score >= 4) | 57.1 (28.9 to 82.3) | 64.9 (47.5 to 79.8) |
Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection (Day 1) to the end of the study follow-up. The median time on follow-up was 385.5, 132.5, 130.5, 255.5, 252.0, 256.5, 250.0, 119.5, 385.0, and 386.0 days for arms Part 1: Risankizumab (Risa), Part 2 Period A (P2PA): Risa, P2PA: Ustekinumab (Uste), P2PB: Uste/Risa, P2PB Non-responders/Risa, P2PB Responders/Risa, P2PB Treatment Withdrawal, P2PC: Risa, P3: Risa, and P4: Risa respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Risankizumab | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Part 2 Period A: Risankizumab | 0/54 (0%) | 0/54 (0%) | 21/54 (38.9%) |
| Part 2 Period A: Ustekinumab | 0/28 (0%) | 0/28 (0%) | 11/28 (39.3%) |
| Part 2 Period A: Ustekinumab; Period B: Risankizumab | 0/28 (0%) | 1/28 (3.6%) | 19/28 (67.9%) |
| Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab | 0/10 (0%) | 1/10 (10%) | 8/10 (80%) |
| Part 2 Period A Risankizumab Responders; Period B: Risankizumab | 0/22 (0%) | 0/22 (0%) | 13/22 (59.1%) |
| Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal | 0/21 (0%) | 1/21 (4.8%) | 11/21 (52.4%) |
| Part 2 Period C: Risankizumab | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Part 3: Risankizumab | 0/13 (0%) | 0/13 (0%) | 6/13 (46.2%) |
| Part 4: Risankizumab | 0/32 (0%) | 0/32 (0%) | 23/32 (71.9%) |
| Event | Part 1: Risankizumab | Part 2 Period A: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Ustekinumab; Period B: Risankizumab | Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal | Part 2 Period C: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|---|---|---|---|---|
| FIBULA FRACTUREInjury, poisoning and procedural complications | 0/12 | 0/54 | 0/28 | 0/28 | 1/10 | 0/22 | 0/21 | 0/8 | 0/13 | 0/32 |
| EOSINOPHILIC OESOPHAGITISGastrointestinal disorders | 0/12 | 0/54 | 0/28 | 0/28 | 0/10 | 0/22 | 1/21 | 0/8 | 0/13 | 0/32 |
| SUICIDAL IDEATIONPsychiatric disorders | 0/12 | 0/54 | 0/28 | 1/28 | 0/10 | 0/22 | 0/21 | 0/8 | 0/13 | 0/32 |
| Event | Part 1: Risankizumab | Part 2 Period A: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Ustekinumab; Period B: Risankizumab | Part 2 Period A Risankizumab Non-responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Risankizumab | Part 2 Period A Risankizumab Responders; Period B: Treatment Withdrawal | Part 2 Period C: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab |
|---|---|---|---|---|---|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 0/12 | 10/54 | 4/28 | 12/28 | 4/10 | 5/22 | 2/21 | 0/8 | 1/13 | 10/32 |
| PYREXIAGeneral disorders | 2/12 | 0/54 | 0/28 | 2/28 | 0/10 | 0/22 | 0/21 | 2/8 | 1/13 | 4/32 |
| COVID-19Infections and infestations | 1/12 | 5/54 | 2/28 | 1/28 | 2/10 | 1/22 | 2/21 | 0/8 | 1/13 | 0/32 |
| HEADACHENervous system disorders | 2/12 | 3/54 | 3/28 | 3/28 | 0/10 | 4/22 | 1/21 | 0/8 | 0/13 | 1/32 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/12 | 1/54 | 0/28 | 1/28 | 1/10 | 2/22 | 1/21 | 0/8 | 2/13 | 1/32 |
| COUGHRespiratory, thoracic and mediastinal disorders | 0/12 | 1/54 | 0/28 | 3/28 | 1/10 | 1/22 | 1/21 | 0/8 | 2/13 | 3/32 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 0/12 | 1/54 | 0/28 | 1/28 | 0/10 | 0/22 | 3/21 | 0/8 | 0/13 | 0/32 |
| SKIN PAPILLOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/12 | 0/54 | 0/28 | 0/28 | 0/10 | 3/22 | 0/21 | 0/8 | 0/13 | 2/32 |
| CHILLSGeneral disorders | 1/12 | 0/54 | 0/28 | 1/28 | 0/10 | 0/22 | 0/21 | 1/8 | 0/13 | 0/32 |
| BACTERIAL VAGINOSISInfections and infestations | 0/12 | 0/54 | 0/28 | 0/28 | 0/10 | 0/22 | 0/21 | 1/8 | 0/13 | 0/32 |
The Intent to Treat (ITT) Population included all enrolled participants in from Parts 1, 3, and 4, and all randomized participants from Part 2.
| Age, Customized(Participants) | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab | Total |
|---|---|---|---|---|---|---|
| 6 to < 9 years | 0 | 0 | 0 | 3 | 10 | 13 |
| 9 to < 12 years | 0 | 0 | 0 | 10 | 20 | 30 |
| 12 to <15 years | 5 | 14 | 22 | 0 | 0 | 41 |
| 15 to <18 years | 7 | 14 | 32 | 0 | 0 | 53 |
| Sex: Female, Male(Participants) | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab | Total |
|---|---|---|---|---|---|---|
| Female | 7 | 15 | 31 | 9 | 18 | 80 |
| Male | 5 | 13 | 23 | 4 | 12 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 8 | 1 | 0 | 17 |
| Not Hispanic or Latino | 10 | 22 | 46 | 12 | 30 | 120 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 1 | 6 | 2 | 3 | 7 | 19 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 2 | 1 | 3 | 0 | 2 | 8 |
| White | 6 | 20 | 48 | 10 | 20 | 104 |
| More than one race | 2 | 1 | 1 | 0 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Psoriasis Area and Severity Index (PASI) Score(score on a scale) | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab | Total |
|---|---|---|---|---|---|---|
| Mean | 21.43 ± 8.124 | 16.55 ± 7.229 | 16.39 ± 4.909 | 26.21 ± 9.158 | 18.59 ± 9.211 | 18.28 ± 7.716 |
| Static Physician Global Assessment (sPGA) Category(Participants) | Part 1: Risankizumab | Part 2 Period A: Ustekinumab | Part 2 Period A: Risankizumab | Part 3: Risankizumab | Part 4: Risankizumab | Total |
|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 0 | 2 | 6 | 0 | 3 | 11 |
| 3 | 0 | 25 | 42 | 2 | 23 | 92 |
| 4 | 12 | 1 | 6 | 11 | 4 | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jul 2020 to primary completion in Feb 2024, 42 months.
Results were first posted in May 2025, 1 year 3 months after primary completion. A results delay was requested in Jan 2025.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 42 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab